Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celera Seeks Approval For Coronary Heart Disease Genoytyping Assay

This article was originally published in The Gray Sheet

Executive Summary

Celera is seeking FDA approval for a genetic assay to detect risk of coronary heart disease, including potential use as a therapy guide for the 20-30 million Americans who are being considered for treatment with statin drugs such as Lipitor.

You may also be interested in...



Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase

Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.

Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase

Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.

News In Brief

Quest Diagnostics buys Celera

Related Content

Topics

UsernamePublicRestriction

Register

MT029727

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel